S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
OTCMKTS:IPSEY

Ipsen Stock Forecast, Price & News

$24.00
+0.25 (+1.03%)
(As of 01/14/2022 10:31 AM ET)
Add
Compare
Today's Range
$23.54
$24.00
50-Day Range
$21.71
$26.60
52-Week Range
$19.35
$28.10
Volume
600 shs
Average Volume
2,138 shs
Market Capitalization
$8.04 billion
P/E Ratio
N/A
Dividend Yield
0.79%
Beta
1.14
30 days | 90 days | 365 days | Advanced Chart
Receive IPSEY News and Ratings via Email

Sign-up to receive the latest news and ratings for Ipsen and its competitors with MarketBeat's FREE daily newsletter.


Ipsen logo

About Ipsen

Ipsen SA manufactures pharmaceutical products for oncology, neuroscience and rare diseases. It operates through following segments: Specialty Care and Consumer Healthcare. The Specialty Care segment focuses on Oncology with Somatuline, a somatostatin analog for the treatment of neuroendocrine tumors; Cabometyx, the single-agent treatment with significant improvement across all key efficacy endpoints in second-line renal cell carcinoma; Onivyde, a differentiated product with overall survival benefit addressing a high unmet medical need in pancreatic cancer; and Decapeptyl, an established and growing product in Europe and China for prostate cancer and Rare Diseases with Nutropin, a liquid formulation of recombinant human growth hormone and Increlex, a recombinant insulin-like growth factor of human origin. The Consumer Healthcare segment include brands such as Smecta, a naturally extracted purified clay for the symptomatic treatment of acute diarrhea; Tanakan, a standardized extract from the leaves of Ginkgo biloba for the treatment of various neurological and neuro-sens or ial disorders; Forlax, an osmotic laxative indicated for the symptomatic treatment of constipation in adults an

Headlines

Ipsen (OTCMKTS:IPSEY) Raised to "Buy" at UBS Group
January 11, 2022 |  americanbankingnews.com
Short Interest in Ipsen S.A. (OTCMKTS:IPSEY) Rises By 28.6%
January 8, 2022 |  americanbankingnews.com
Ipsen Pledges Ambitious Action on Climate Change
October 27, 2021 |  finance.yahoo.com
Ipsen Adds Another Program Into Its Pre-Clinical...
October 18, 2021 |  benzinga.com
See More Headlines

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:IPSEY
CIK
N/A
Employees
5,700
Year Founded
N/A

Sales & Book Value

Annual Sales
$3.07 billion
Cash Flow
$2.88 per share
Book Value
$7.23 per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$8.04 billion
Optionable
Not Optionable

Company Calendar

Today
1/17/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

0.99 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.1Dividend Strength: 0.8Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Ipsen (OTCMKTS:IPSEY) Frequently Asked Questions

Is Ipsen a buy right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ipsen in the last twelve months. There are currently 2 sell ratings, 5 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Ipsen stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IPSEY, but not buy additional shares or sell existing shares.
View analyst ratings for Ipsen
or view top-rated stocks.

How has Ipsen's stock price been impacted by COVID-19 (Coronavirus)?

Ipsen's stock was trading at $14.4150 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, IPSEY shares have increased by 66.5% and is now trading at $23.9950.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Ipsen?

Ipsen saw a drop in short interest in December. As of December 31st, there was short interest totaling 700 shares, a drop of 22.2% from the December 15th total of 900 shares. Based on an average daily trading volume, of 5,600 shares, the days-to-cover ratio is presently 0.1 days.
View Ipsen's Short Interest
.

How often does Ipsen pay dividends? What is the dividend yield for Ipsen?

Ipsen announced a dividend on Tuesday, May 25th. Shareholders of record on Monday, May 31st will be given a dividend of $0.5877 per share on Wednesday, June 9th. This represents a yield of 2.21%. The ex-dividend date of this dividend is Friday, May 28th.
View Ipsen's dividend history
.

Is Ipsen a good dividend stock?

Ipsen pays an annual dividend of $0.19 per share and currently has a dividend yield of 0.79%.
View Ipsen's dividend history.

Who are Ipsen's key executives?

Ipsen's management team includes the following people:
  • David G. Loew, Chief Executive Officer & Director
  • Aymeric Le Chatelier, Chief Financial Officer & Executive Vice President
  • Aidan Murphy, Executive Vice President-Technical Operations
  • Howard Mayer, Executive Vice President-Research & Development
  • Steven Hildemann, Chief Medical Officer & Executive Vice President

What is Ipsen's stock symbol?

Ipsen trades on the OTCMKTS under the ticker symbol "IPSEY."

How do I buy shares of Ipsen?

Shares of IPSEY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ipsen's stock price today?

One share of IPSEY stock can currently be purchased for approximately $24.00.

How much money does Ipsen make?

Ipsen has a market capitalization of $8.04 billion and generates $3.07 billion in revenue each year.

How many employees does Ipsen have?

Ipsen employs 5,700 workers across the globe.

What is Ipsen's official website?

The official website for Ipsen is www.ipsen.com.

Where are Ipsen's headquarters?

How can I contact Ipsen?

Ipsen's mailing address is 65 quai Georges Gorse, Boulogne-Billancourt cedex I0, 92650. The company can be reached via phone at (315) 833-5000, via email at [email protected], or via fax at 33-01-58-33-50-01.


This page was last updated on 1/17/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.